Cargando…

Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention

BACKGROUND: Restenosis represents the major limiting factor for the long-term efficacy of percutaneous coronary intervention (PCI). Several genetic factors involved in the regulation of the vascular system have been described to play a role in the pathogenesis of restenosis. We investigated whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Kullmann, Silke, Binner, Priska, Rackebrandt, Kirsten, Huge, Andreas, Haltern, Georg, Lankisch, Mark, Füth, Reiner, von Hodenberg, Eberhard, Bestehorn, Hans-Peter, Scheffold, Thomas
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767343/
https://www.ncbi.nlm.nih.gov/pubmed/19814804
http://dx.doi.org/10.1186/1471-2261-9-48
_version_ 1782173304598036480
author Kullmann, Silke
Binner, Priska
Rackebrandt, Kirsten
Huge, Andreas
Haltern, Georg
Lankisch, Mark
Füth, Reiner
von Hodenberg, Eberhard
Bestehorn, Hans-Peter
Scheffold, Thomas
author_facet Kullmann, Silke
Binner, Priska
Rackebrandt, Kirsten
Huge, Andreas
Haltern, Georg
Lankisch, Mark
Füth, Reiner
von Hodenberg, Eberhard
Bestehorn, Hans-Peter
Scheffold, Thomas
author_sort Kullmann, Silke
collection PubMed
description BACKGROUND: Restenosis represents the major limiting factor for the long-term efficacy of percutaneous coronary intervention (PCI). Several genetic factors involved in the regulation of the vascular system have been described to play a role in the pathogenesis of restenosis. We investigated whether the EPHX2 K55R polymorphism, previously linked to significantly higher risk for coronary heart disease (CHD), was associated with the occurrence of restenosis after PCI. The association with incident CHD should have been confirmed and a potential correlation of the EPHX2 K55R variant to an increased risk of hypertension was analysed. METHODS: An overall cohort of 706 patients was studied: This cohort comprised of 435 CHD patients who had undergone successful PCI. Follow-up coronary angiography in all patients was performed 6 months after intervention. Another 271 patients in whom CHD had been excluded by coronary angiography served as controls. From each patient EDTA-blood was drawn at the baseline ward round. Genomic DNA was extracted from these samples and genotyping was performed by real-time PCR and subsequent melting curve analysis. RESULTS: In CHD patients 6 month follow-up coronary angiography revealed a restenosis rate of 29.4%, classified as late lumen loss as well as lumen re-narrowing ≥ 50%. Statistical analysis showed an equal genotype distribution in restenosis patients and non-restenosis patients (A/A 82.0% and A/G + G/G 18.0% versus A/A 82.1% and A/G + G/G 17.9%). Moreover, neither a significant difference in the genotype distribution of CHD patients and controls nor an association with increased risk of hypertension was found. CONCLUSION: The results of the present study indicate that the EPHX2 K55R polymorphism is not associated with restenosis after PCI, with incidence of CHD, or with an increased risk of hypertension and therefore, can not serve as a predictor for risk of CHD or restenosis after PCI.
format Text
id pubmed-2767343
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27673432009-10-27 Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention Kullmann, Silke Binner, Priska Rackebrandt, Kirsten Huge, Andreas Haltern, Georg Lankisch, Mark Füth, Reiner von Hodenberg, Eberhard Bestehorn, Hans-Peter Scheffold, Thomas BMC Cardiovasc Disord Research Article BACKGROUND: Restenosis represents the major limiting factor for the long-term efficacy of percutaneous coronary intervention (PCI). Several genetic factors involved in the regulation of the vascular system have been described to play a role in the pathogenesis of restenosis. We investigated whether the EPHX2 K55R polymorphism, previously linked to significantly higher risk for coronary heart disease (CHD), was associated with the occurrence of restenosis after PCI. The association with incident CHD should have been confirmed and a potential correlation of the EPHX2 K55R variant to an increased risk of hypertension was analysed. METHODS: An overall cohort of 706 patients was studied: This cohort comprised of 435 CHD patients who had undergone successful PCI. Follow-up coronary angiography in all patients was performed 6 months after intervention. Another 271 patients in whom CHD had been excluded by coronary angiography served as controls. From each patient EDTA-blood was drawn at the baseline ward round. Genomic DNA was extracted from these samples and genotyping was performed by real-time PCR and subsequent melting curve analysis. RESULTS: In CHD patients 6 month follow-up coronary angiography revealed a restenosis rate of 29.4%, classified as late lumen loss as well as lumen re-narrowing ≥ 50%. Statistical analysis showed an equal genotype distribution in restenosis patients and non-restenosis patients (A/A 82.0% and A/G + G/G 18.0% versus A/A 82.1% and A/G + G/G 17.9%). Moreover, neither a significant difference in the genotype distribution of CHD patients and controls nor an association with increased risk of hypertension was found. CONCLUSION: The results of the present study indicate that the EPHX2 K55R polymorphism is not associated with restenosis after PCI, with incidence of CHD, or with an increased risk of hypertension and therefore, can not serve as a predictor for risk of CHD or restenosis after PCI. BioMed Central 2009-10-08 /pmc/articles/PMC2767343/ /pubmed/19814804 http://dx.doi.org/10.1186/1471-2261-9-48 Text en Copyright © 2009 Kullmann et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kullmann, Silke
Binner, Priska
Rackebrandt, Kirsten
Huge, Andreas
Haltern, Georg
Lankisch, Mark
Füth, Reiner
von Hodenberg, Eberhard
Bestehorn, Hans-Peter
Scheffold, Thomas
Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention
title Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention
title_full Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention
title_fullStr Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention
title_full_unstemmed Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention
title_short Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention
title_sort variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767343/
https://www.ncbi.nlm.nih.gov/pubmed/19814804
http://dx.doi.org/10.1186/1471-2261-9-48
work_keys_str_mv AT kullmannsilke variationinthehumansolubleepoxidehydrolasegeneandriskofrestenosisafterpercutaneouscoronaryintervention
AT binnerpriska variationinthehumansolubleepoxidehydrolasegeneandriskofrestenosisafterpercutaneouscoronaryintervention
AT rackebrandtkirsten variationinthehumansolubleepoxidehydrolasegeneandriskofrestenosisafterpercutaneouscoronaryintervention
AT hugeandreas variationinthehumansolubleepoxidehydrolasegeneandriskofrestenosisafterpercutaneouscoronaryintervention
AT halterngeorg variationinthehumansolubleepoxidehydrolasegeneandriskofrestenosisafterpercutaneouscoronaryintervention
AT lankischmark variationinthehumansolubleepoxidehydrolasegeneandriskofrestenosisafterpercutaneouscoronaryintervention
AT futhreiner variationinthehumansolubleepoxidehydrolasegeneandriskofrestenosisafterpercutaneouscoronaryintervention
AT vonhodenbergeberhard variationinthehumansolubleepoxidehydrolasegeneandriskofrestenosisafterpercutaneouscoronaryintervention
AT bestehornhanspeter variationinthehumansolubleepoxidehydrolasegeneandriskofrestenosisafterpercutaneouscoronaryintervention
AT scheffoldthomas variationinthehumansolubleepoxidehydrolasegeneandriskofrestenosisafterpercutaneouscoronaryintervention